Evaluating a new drug for advanced solid tumors with a specific genetic deletion

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the mass balance, metabolism, elimination, and drug levels of [14C]-BMS-986504 (MRTX1719) in participants who have advanced solid tumors with a homozygous deletion of the methylthioadenosine phosphorylase (MTAP) gene. It aims to understand how the drug behaves in the body and its potential effectiveness in this specific patient population. Participants must have previously received or been intolerant to standard cancer treatments. The study is interventional and is classified as Phase 1, focusing on the pharmacokinetics of the drug.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Participants must have an advanced, unresectable, or metastatic solid tumor malignancy with a deletion of the methylthioadenosine phosphorylase (MTAP) gene.
* Participants must have received, be refractory to, be ineligible for, or be intolerant of available standard care for their cancer.

Exclusion Criteria

* Participants must not have a history of any surgical or medical conditions possibly affecting how the study drug is distributed, broken down (metabolized) and removed (excreted or eliminated) from the body.
* Participants must not have participated in a clinical study involving a radiolabeled study drug within 12 months prior to admission to the research center.
* Participants must not have a current or recent (within 3 months of study drug administration) gastrointestinal disease.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Where it's running

• ICON / PRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely
  Budapest, Hungary Recruiting
• START Rioja, The START Center for cancer research
  Logroño, Spain Recruiting
• Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid,
  Madrid, Spain Recruiting

Study contacts

• Study coordinator: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
• Email: Clinical.Trials@bms.com
• Phone: 855-907-3286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Navlimetostat: how foods and other drugs affect its levels in healthy adult women

  This study tests how what you eat and certain medicines change the amount of Navlimetostat in healthy adult women.

  Recruiting Phase 1 Bristol-Myers Squibb · Québec, Quebec · NCT07800897

• Effect of a single dose of BMS-986446 in healthy adults and after multiple doses in people with early Alzheimer's

  This study tests how BMS-986446 behaves in the body after a single dose in healthy adults and after multiple doses in people with early Alzheimer's disease to see safety and immune response.

  Recruiting Phase 1 Bristol-Myers Squibb · Anaheim, California and 5 other locations · NCT07780383

• How Navlimetostat is processed in healthy women

  This study tests how Navlimetostat is broken down and cleared in healthy women to understand its metabolism and levels in the body.

  Recruiting Phase 1 Bristol-Myers Squibb · Madison, Wisconsin and 1 other locations · NCT07777133

• Golcadomide pharmacokinetics and safety in severe kidney impairment and ESRD

  This study tests how golcadomide behaves in the body and whether it is safe in adults with severe kidney problems or end-stage kidney disease, compared with people with normal kidney function.

  Recruiting at 3 sites Phase 1 Bristol-Myers Squibb · Chandler, Arizona and 2 other locations · NCT07763418

• Repotrectinib safety in children with NTRK fusion cancers in Japan

  This study tests the safety of repotrectinib in children and teens with NTRK fusion–positive solid tumors in Japan during routine care.

  Recruiting at 2 sites Bristol-Myers Squibb · Minato-ku, Tokyo and 1 other locations · NCT07755826

• First-line luspatercept use in adults with lower-risk transfusion-dependent MDS

  This study follows adults with lower-risk MDS who start luspatercept as part of usual care to see how often they need fewer transfusions and how their blood counts and quality of life change over up to two years.

  Recruiting Bristol-Myers Squibb · Mainz · NCT07752121

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.